In the DZIF, scientists from the universities of Tübingen, Münster and Munich join forces and prepare together with the company Hyglos clinical studies on an active substance against the dreaded
The DZIF has initiated an online consultation service for treating cases of multidrug-resistant tuberculosis. Here, doctors can submit their cases and get advice for further treatment from experts at
30 years after HIV was discovered to be the cause of the acquired immune deficiency syndrome AIDS, and despite intensive research, no vaccine or cure has yet been found. An international team of
The initial results of a clinical Phase I trial of a potential vaccine against the dreaded Ebola virus are now available. At the Hamburg-Eppendorf University Medical Center (UKE), in Geneva
DZIF infectious disease and tropical medicine specialist Günter Fröschl (42), from Munich, spent two months in Liberia from December last year, to help with the largest Ebola epidemic seen to date
DZIF researcher Oliver Cornely has been elected as a Fellow of the American Academy of Microbiology (AAM) in honour of his achievements in the field of life-threatening infections in immunocompromised
A patient who had contracted the dangerous MERScoronavirus in Abu Dhabi gave rise to public concern in Osnabrück this weekend. Many people fear a spread of the pathogen, which causes severe pneumonia
PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics, presented the results of its most recent phase IIb study. The most exciting finding from the study is that high
In the journal The Lancet, DZIF researchers from the Research Center Borstel and their colleagues from England and South Africa make the case for optimising tuberculosis drug development. They
From chemistry to biology to medicine—during the course of his career, Mark Brönstrup repeatedly crossed the boundaries between these disciplines. So it comes as no surprise that today he is head of
